Jake Gockley

Jake Gockley

Auto-generated profile, based on publicly available information

Jake Gockley

Sage Bionetworks Seattle WA USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Cell
Verified
Journal Article
Closed access
AWA. Jeremy Willsey
A. Jeremy Willsey
JSJan Stefan Sanders
Jan Stefan Sanders
MLMingfeng Li
Mingfeng Li
SDShan Dong
Shan Dong
ATAndrew T. Tebbenkamp
Andrew T. Tebbenkamp
MSMatthew W. State
Matthew W. State

1 October 2014 in Cell Reports
Verified
Journal Article
Open access
SDShan Dong
Shan Dong
MWMichael F. Walker
Michael F. Walker
NCNicholas J. Carriero
Nicholas J. Carriero
MDMichael DiCola
Michael DiCola
AWA. Jeremy Willsey
A. Jeremy Willsey
JSJan Stefan Sanders
Jan Stefan Sanders
Whole-exome sequencing (WES) studies have demonstrated the contribution of de novo loss-of-function single-nucleotide variants (SNVs) to autism spectrum disorder (ASD). However, challenges in the reliable detection of de novo insertions and deletions (indels) have limited inclusion of these variants in prior analyses. By applying a robust indel detection method to WES data from 787 ASD families (2,963 individuals), we demonstrate that de novo frameshift indels contribute to ASD risk (OR = 1.6; 95% CI = 1.0-2.7; p = 0.03), are more common in female probands (p = 0.02), are enriched among genes encoding FMRP targets (p = 6 × 10(-9)), and arise predominantly on the paternal chromosome (p < 0.001). On the basis of mutation rates in probands versus unaffected siblings, we conclude that de novo frameshift indels contribute to risk in approximately 3% of individuals with ASD. Finally, by observing clustering of mutations in unrelated probands, we uncover two ASD-associated genes: KMT2E (MLL5), a chromatin regulator, and RIMS1, a regulator of synaptic vesicle release.

28 December 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SUSeverin Uebbing
Severin Uebbing
JGJake Gockley
Jake Gockley
SRSteven K. Reilly
Steven K. Reilly
AKAcadia A. Kocher
Acadia A. Kocher
EGEvan Geller
Evan Geller
JNJames P. Noonan
James P. Noonan
Significance: Uniquely human biology is the result of genetic differences between humans and other primates, but identifying the critical changes still poses a major challenge. We screened >32,000 human-specific substitutions in two classes of putative transcriptional enhancers implicated in human evolution for their effects on enhancer activity in human neural stem cells, a cell type fundamental for cortical development and expansion. We identify hundreds of substitutions that modify enhancer activity either alone or in combination with other variants. We find different patterns of substitution effects in different enhancer types. Our data support substitutions often interacting by modifying the same transcription factor binding sites. The functional substitutions we identify provide a rich set of candidate loci for studies of human-specific regulatory evolution.

25 April 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DEDeena Emera
Deena Emera
JYJun Yin
Jun Yin
SRSteven K. Reilly
Steven K. Reilly
JGJake Gockley
Jake Gockley
JNJames P. Noonan
James P. Noonan
Morphological innovations such as the mammalian neocortex may involve the evolution of novel regulatory sequences. However, de novo birth of regulatory elements active during morphogenesis has not been extensively studied in mammals. Here, we use H3K27ac-defined regulatory elements active during human and mouse corticogenesis to identify enhancers that were likely active in the ancient mammalian forebrain. We infer the phylogenetic origins of these enhancers and find that ∼20% arose in the mammalian stem lineage, coincident with the emergence of the neocortex. Implementing a permutation strategy that controls for the nonrandom variation in the ages of background genomic sequences, we find that mammal-specific enhancers are overrepresented near genes involved in cell migration, cell signaling, and axon guidance. Mammal-specific enhancers are also overrepresented in modules of coexpressed genes in the cortex that are associated with these pathways, notably ephrin and semaphorin signaling. Our results also provide insight into the mechanisms of regulatory innovation in mammals. We find that most neocortical enhancers did not originate by en bloc exaptation of transposons. Young neocortical enhancers exhibit smaller H3K27ac footprints and weaker evolutionary constraint in eutherian mammals than older neocortical enhancers. Based on these observations, we present a model of the enhancer life cycle in which neocortical enhancers initially emerge from genomic background as short, weakly constrained “proto-enhancers.” Many proto-enhancers are likely lost, but some may serve as nucleation points for complex enhancers to evolve. Significance The neocortex mediates complex cognitive and motor tasks in all mammals. A long-debated question is how this complex structure evolved in primitive mammals. Here we investigate the role of novel mammalian gene regulatory sequences in the emergence of the neocortex and the mechanisms by which these sequences emerged. We find that ∼20% of elements active during human and mouse neocortical development were born in early mammals. These novel mammalian elements enrich for cell migration, cell signaling, and axon guidance functions, implicating these processes in neocortical origins. In contrast to recent studies, we propose a model in which novel regulatory elements emerge as short sequences of minimal biological significance. Many disappear, but those that survive become increasingly complex over time.

4 November 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
SDSamuel A. Danziger
Samuel A. Danziger
MMMark McConnell
Mark McConnell
JGJake Gockley
Jake Gockley
MYMary H. Young
Mary H. Young
ARAdam Rosenthal
Adam Rosenthal
GMGareth John Morgan
Gareth John Morgan
The tumor microenvironment (TME) is increasingly appreciated as an important determinant of cancer outcome, including in multiple myeloma (MM). However, most myeloma microenvironment studies have been based on bone marrow (BM) aspirates, which often do not fully reflect the cellular content of BM tissue itself. To address this limitation in myeloma research, we systematically characterized the whole bone marrow (WBM) microenvironment during premalignant, baseline, on treatment, and post-treatment phases. Between 2004 and 2019, 998 BM samples were taken from 436 patients with newly diagnosed MM (NDMM) at the University of Arkansas for Medical Sciences in Little Rock, Arkansas, United States of America. These patients were 61% male and 39% female, 89% White, 8% Black, and 3% other/refused, with a mean age of 58 years. Using WBM and matched cluster of differentiation (CD)138-selected tumor gene expression to control for tumor burden, we identified a subgroup of patients with an adverse TME associated with 17 fewer months of progression-free survival (PFS) (95% confidence interval [CI] 5–29, 49–69 versus 70–82 months, χ2 p = 0.001) and 15 fewer months of overall survival (OS; 95% CI –1 to 31, 92–120 versus 113–129 months, χ2 p = 0.036). Using immunohistochemistry-validated computational tools that identify distinct cell types from bulk gene expression, we showed that the adverse outcome was correlated with elevated CD8+ T cell and reduced granulocytic cell proportions. This microenvironment develops during the progression of premalignant to malignant disease and becomes less prevalent after therapy, in which it is associated with improved outcomes. In patients with quantified International Staging System (ISS) stage and 70-gene Prognostic Risk Score (GEP-70) scores, taking the microenvironment into consideration would have identified an additional 40 out of 290 patients (14%, premutation p = 0.001) with significantly worse outcomes (PFS, 95% CI 6–36, 49–73 versus 74–90 months) who were not identified by existing clinical (ISS stage III) and tumor (GEP-70) criteria as high risk. The main limitations of this study are that it relies on computationally identified cell types and that patients were treated with thalidomide rather than current therapies. In this study, we observe that granulocyte signatures in the MM TME contribute to a more accurate prognosis. This implies that future researchers and clinicians treating patients should quantify TME components, in particular monocytes and granulocytes, which are often ignored in microenvironment studies.

4 May 2021 in Genome Medicine
Verified
Journal Article
Open access
PDF file
JGJake Gockley
Jake Gockley
KMKelsey S. Montgomery
Kelsey S. Montgomery
WPWilliam L. Poehlman
William L. Poehlman
JWJesse C. Wiley
Jesse C. Wiley
YLYue Liu
Yue Liu
BLBenjamin A. Logsdon
Benjamin A. Logsdon
Background: Alzheimer’s disease (AD) is an incurable neurodegenerative disease currently affecting 1.75% of the US population, with projected growth to 3.46% by 2050. Identifying common genetic variants driving differences in transcript expression that confer AD risk is necessary to elucidate AD mechanism and develop therapeutic interventions. We modify the FUSION transcriptome-wide association study (TWAS) pipeline to ingest gene expression values from multiple neocortical regions. Methods: A combined dataset of 2003 genotypes clustered to 1000 Genomes individuals from Utah with Northern and Western European ancestry (CEU) was used to construct a training set of 790 genotypes paired to 888 RNASeq profiles from temporal cortex (TCX = 248), prefrontal cortex (FP = 50), inferior frontal gyrus (IFG = 41), superior temporal gyrus (STG = 34), parahippocampal cortex (PHG = 34), and dorsolateral prefrontal cortex (DLPFC = 461). Following within-tissue normalization and covariate adjustment, predictive weights to impute expression components based on a gene’s surrounding cis-variants were trained. The FUSION pipeline was modified to support input of pre-scaled expression values and support cross validation with a repeated measure design arising from the presence of multiple transcriptome samples from the same individual across different tissues. Results: Cis-variant architecture alone was informative to train weights and impute expression for 6780 (49.67%) autosomal genes, the majority of which significantly correlated with gene expression; FDR < 5%: N = 6775 (99.92%), Bonferroni: N = 6716 (99.06%). Validation of weights in 515 matched genotype to RNASeq profiles from the CommonMind Consortium (CMC) was (72.14%) in DLPFC profiles. Association of imputed expression components from all 2003 genotype profiles yielded 8 genes significantly associated with AD (FDR < 0.05): APOC1, EED, CD2AP, CEACAM19, CLPTM1, MTCH2, TREM2, and KNOP1. Conclusions: We provide evidence of cis-genetic variation conferring AD risk through 8 genes across six distinct genomic loci. Moreover, we provide expression weights for 6780 genes as a valuable resource to the community, which can be abstracted across the neocortex and a wide range of neuronal phenotypes.